CJC-1295 (No DAC) 2mg

In stock

Lab tested · Mar 2023
£17.95

Supplied for Research Purposes Only. This product and the information provided are intended solely for laboratory research. We do not provide guidance on human use. These products are for sale to persons aged 18 and over only. Customers are responsible for checking the legal status of the product in their own jurisdiction before purchase.

CJC-1295 (No DAC) 2mg is supplied in a research vial. Commonly called modified GRF(1-29), this GHRH-fragment analogue is associated with research on pituitary GH signalling and is distinct from the albumin-binding DAC form.

Check out our Independent Lab Analysis (opens in a new window).

For information on reconstituting peptides, see our guide: How to Reconstitute Peptides with Bacteriostatic Water: A Step-by-Step Guide .

Certificate of analysis

Independently tested by MZ Biolabs

All lab reports
View full certificate from 1 March 2023 (PDF, opens in a new tab)

Latest result

Most recent test
  • 99.9% Purity
  • 2 mg Calculated amount 99.9% purity of 2 mg
Sample tested
Not stated
Analysis date
1 March 2023
Laboratory
MZ Biolabs
Lab lot
2023-02-27
Identity
Molecular weight confirmed
Method
Mass Spectrometry and UV

Testing history

  1. 1 March 2023 Purity 99.9% PDF
  2. 16 June 2021 Purity 100% PDF

CJC-1295 No DAC in GHRH research

CJC-1295 (No DAC) 2mg is the catalogue designation for the non-DAC modified GHRH-fragment peptide commonly called modified GRF(1-29). Its research context centres on the GHRH receptor and the pituitary signals involved in growth hormone release.

Understanding the modified GRF name

GRF is another name for growth hormone-releasing factor. Research on modified fragments seeks to retain receptor activity while changing properties such as susceptibility to peptide breakdown. Analytical work has characterised a 29-amino-acid amidated preparation associated with the CJC-1295 name, making sequence and terminal chemistry useful details when comparing materials.

What distinguishes the DAC form?

The drug affinity complex in long-acting CJC-1295 enables albumin binding. That design was investigated in preclinical work and human studies showing prolonged GH and IGF-I responses. The No DAC designation marks a meaningful structural difference, so those duration findings should stay attached to the molecule actually tested.

This research offers insight into how GHRH analogues influence endocrine signalling. It also distinguishes the GHRH pathway from ghrelin-receptor secretagogues such as ipamorelin. Clinical body-composition and recovery outcomes for the No DAC material remain separate questions from receptor activity.

Also known as / branded as

  • CJC-1295 without DAC
  • Modified GRF(1-29)
  • Mod GRF(1-29)

Products are supplied for research purposes only and are for sale to persons aged 18 and over.